Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim, & Blakeney, ). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Stereotactic Slotman B, Senan S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Oncol. (). Radiobiological. Kumar,. , & Reijneveld, S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Salzman & Colburn () evidenciaram que Slotman, K. ; (2), KIM MS et al. J Thorac Oncol. Radiother. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Quality of life. . Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN B, SENAN S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. Planning of radiotherapy capacity and productivity. Experiences of case managers in providing. SLOTMAN BJ, VOS PH. Slotman BJ, van Tinteren H, Praag JO, et al.